RT Journal Article
SR Electronic
T1 Analysis of Melanoma in African American Patients in the United States
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6333
OP 6337
DO 10.21873/anticanres.13844
VO 39
IS 11
A1 DANIEL BOCZAR
A1 DAVID J. RESTREPO
A1 ANDREA SISTI
A1 MARIA T. HUAYLLANI
A1 HUMZA Y. SALEEM
A1 XIAONA LU
A1 GABRIELA CINOTTO
A1 OSCAR J. MANRIQUE
A1 AARON C. SPAULDING
A1 ANTONIO J. FORTE
YR 2019
UL http://ar.iiarjournals.org/content/39/11/6333.abstract
AB Background/Aim: To characterize the demographics, tumor staging and treatment of African American (AA) patients diagnosed with melanoma in the United States. Patients and Methods: The National Cancer Database was used to extrapolate data from patients with melanoma between January 1, 2004, and December 31, 2015. The patients were then further divided based on ethnicity (AAs vs. Caucasians) to compare patient efficacy of treatment. Results: The mean time for AA patients to receive treatment was 20.37 days compared with 11.25 days for Caucasians (p<0.001), while time to surgery was 38.86 days compared to 31.12 days for Caucasians (p<0.001). Moreover, AA race was a predictor of American Joint Committee on Cancer stage greater than II, tumor diagnosed at autopsy, presence of ulceration, and distribution in the extremities. Conclusion: AA patients with melanoma are more likely to have worse tumor staging, treatment delay, treatment at an Integrated Cancer Program, and diagnosis at autopsy.